Warfarin is recognized as the standard antithrombotic agent for stroke prevention. However. new oral anticoagulant such as dabigatran constitutes huge improvement to compensate for the limitation of warfarin. A literature review was performed to compare and contrast the overall benefit of dabigatran and warfarin among patients with atrial fibrillation. https://www.ngetikin.com/special-pick-MVP4-Moisture-Vapor-Protection-Anti-Fracture-and-Noise-Reduction-Membrane-special-save/